Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme

被引:56
作者
Chavarria-Soley, Gabriela [1 ]
Sticht, Heinrich [2 ]
Aklillu, Eleni [3 ]
Ingelman-Sundberg, Magnits [4 ]
Pasutto, Francesca [1 ]
Reis, Andre [1 ]
Rautenstrauss, Bernd [1 ]
机构
[1] Univ Erlangen Nurnberg, Inst Human Genet, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Div Clin Pharmacol, Stockholm, Sweden
[4] Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, Stockholm, Sweden
关键词
cytochrome P450IBI; CYP1B1; primary congenital glaucoma; PCG; enzymatic activity; background haplotype;
D O I
10.1002/humu.20786
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Primary congenital glaucoma (PCG) is an autosomal recessive disorder caused predominantly by mutations in the CYP1B1 gene. A total of five frequent single nucleotide polymorphisms (SNPs) have been identified in the coding sequence of CYP1B1: rs10012C>G (p.R48G), rs1056827G>T (p.A119S), rs1056836C>G (p.V432L), rs1056837C>T (p.D449D), and rs1800440A>G (p.N453S). We performed a functional characterization of four common CYP1B1 variants presenting different coding SNP haplotypes (RAVDN, GSLDN, RALDS, and RALDN) and five CYP1B1 mutations reported for PCG patients: c.182G>A (p.G61E), c.608A>G (p.N203S), c.1033_1035del (p.L343del), c.241 T>A (p.Y81N), and c.685G>A (p.E229K). Each mutation was embedded in its corresponding background SNP haplotype. The common variants revealed variation in enzymatic activity; among them, RAVDN showed the highest activity. Mutants p.G61E, p.N203S, and p.L343del each revealed a residual activity (< 10%) of their respective haplotype. The microsomal CYP1B1 abundance relative to total protein also showed variation in common variants and a significant reduction in p.L343del, p.Y8 IN, and p.E229 K. The free energy of folding (Delta Delta G) values suggest that the lower stability of the mutants is one key property leading to the experimentally observed lower protein abundance. Our new measure of relative enzymatic activity (U/mg total protein), which combines activity and abundance values, was significantly lower for all five mutations compared to the corresponding background haplotype. We classified p.Y81N and p.E229K not as mutations but as hypomorphic alleles, since their relative activity values are intermediate between bona fide mutations and the common variant with the lowest activity (RALDS). We propose that CYP1B1 Mutations can act by either reducing enzymatic activity (p.G61E and p.N203S), reducing the abundance of the enzyme (p.Y81N and p.E229K), or both (p.L343del).
引用
收藏
页码:1147 / 1153
页数:7
相关论文
共 42 条
[1]  
Acharya M, 2006, MOL VIS, V12, P399
[2]   Cytochrome P450 gene polymorphism and cancer [J].
Agúndez, JAG .
CURRENT DRUG METABOLISM, 2004, 5 (03) :211-224
[3]   Anti-apoptotic role of retinoic acid in the inner ear of noise-exposed mice [J].
Ahn, JH ;
Kang, HH ;
Kim, YJ ;
Chung, JW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 335 (02) :485-490
[4]   Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population [J].
Aklillu, E ;
Oscarson, M ;
Hidestrand, M ;
Leidvik, B ;
Otter, C ;
Ingelman-Sundberg, M .
MOLECULAR PHARMACOLOGY, 2002, 61 (03) :586-594
[5]   Characterization of common CYP1B1 variants with different capacity for benzo[a] pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene [J].
Aklillu, E ;
Ovrebo, S ;
Botnen, IV ;
Otter, C ;
Ingelman-Sundberg, M .
CANCER RESEARCH, 2005, 65 (12) :5105-5111
[6]  
Bagiyeva S, 2007, MOL VIS, V13, P1458
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]   Novel CYP1B1 and known PAX6 mutations in anterior segment dysgenesis (ASID) [J].
Chavarria-Soley, Gabriela ;
Michels-Rautenstrauss, Karin ;
Caliebe, Almuth ;
Kautza, Monika ;
Mardin, Christian ;
Rautenstrauss, Bernd .
JOURNAL OF GLAUCOMA, 2006, 15 (06) :499-504
[9]  
Chavarria-Soley G, 2006, MOL VIS, V12, P523
[10]  
Chen H, 2000, DRUG METAB DISPOS, V28, P315